1. Vandetanib decreases tumor incidence and accumulation of HIF-2α, expression of c-Myc and growth factor receptors in the lung of hypoxic mice.
Vandetanib decreases tumor incidence and accumulation of HIF-2α, expression of c-Myc and growth factor receptors in the lung of hypoxic mice. A, tumor incidence in mice (6–9 mice per group) treated with or without vandetanib 75 mg/kg for 15 weeks in normoxia or hypoxia. Vandetanib completely suppresses tumor development in hypoxia but not in normoxia (P = 0.01, Fischer exact test, one-sided). The effect of vandetanib on abundance of HIF1α, HIF2α, c-Myc, angiogenesis factors, and their receptors in normoxia and hypoxia is shown in B–G. Data shown are mean ± SEM and * indicates P ≤ 0.05 for comparisons between untreated normoxia and vandetenib treated in each group.
Vijaya Karoor et al. Cancer Prev Res 2012;5:
©2012 by American Association for Cancer Research